M P Schmid1, M Franckena2, K Kirchheiner3, A Sturdza4, P Georg4, W Dörr3, R Pötter3. 1. Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria. Electronic address: maximilian.schmid@akhwien.at. 2. Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria; Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, Netherlands. 3. Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria; Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria. 4. Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
Abstract
OBJECTIVE: The aim of this study is to investigate patterns of distant relapse after primary radiochemotherapy in cervical cancer patients. METHODS: All patients with cervical cancer treated in curative intent with external beam radiotherapy +/- chemotherapy and image-guided adaptive brachytherapy between January 1998 and June 2009 at the Medical University of Vienna were included in this retrospective analysis. Patients with locoregional recurrences were excluded from this study. Presence, site of and time to distant metastases were recorded. For identifying prognostic factors, uni- and multivariate analyses using Cox regression analysis were performed. Based on the result from the multivariate analysis, patients were stratified into a high and a low risk group. The Kaplan-Meier method was used to estimate distant-metastasis-free-survival in the overall cohort, in the risk groups and for analysing the impact of chemotherapy within the risk groups. RESULTS: A total number of 189 patients were included in this study. After a median follow-up of 54 months, 49 patients developed distant metastases. Overall, distant-metastasis-free-survival 5 years after treatment was 73%. FIGO stage, lymph node status and the extent of tumour regression during treatment were significant predictors for distant metastasis. Distant-metastasis-free-survival 5 years after treatment was 91% and 60% in the low and high risk groups, respectively. The number of the cycles of chemotherapy had a significant impact on the occurrence of distant metastasis in high risk patients, but not in low risk patients. CONCLUSION: Patients with high risk factors have a 40% probability of developing distant metastasis within 5 years. In these patients, decreasing the number of cycles of cisplatin may increase their probability of developing distant metastasis.
OBJECTIVE: The aim of this study is to investigate patterns of distant relapse after primary radiochemotherapy in cervical cancerpatients. METHODS: All patients with cervical cancer treated in curative intent with external beam radiotherapy +/- chemotherapy and image-guided adaptive brachytherapy between January 1998 and June 2009 at the Medical University of Vienna were included in this retrospective analysis. Patients with locoregional recurrences were excluded from this study. Presence, site of and time to distant metastases were recorded. For identifying prognostic factors, uni- and multivariate analyses using Cox regression analysis were performed. Based on the result from the multivariate analysis, patients were stratified into a high and a low risk group. The Kaplan-Meier method was used to estimate distant-metastasis-free-survival in the overall cohort, in the risk groups and for analysing the impact of chemotherapy within the risk groups. RESULTS: A total number of 189 patients were included in this study. After a median follow-up of 54 months, 49 patients developed distant metastases. Overall, distant-metastasis-free-survival 5 years after treatment was 73%. FIGO stage, lymph node status and the extent of tumour regression during treatment were significant predictors for distant metastasis. Distant-metastasis-free-survival 5 years after treatment was 91% and 60% in the low and high risk groups, respectively. The number of the cycles of chemotherapy had a significant impact on the occurrence of distant metastasis in high risk patients, but not in low risk patients. CONCLUSION:Patients with high risk factors have a 40% probability of developing distant metastasis within 5 years. In these patients, decreasing the number of cycles of cisplatin may increase their probability of developing distant metastasis.
Authors: Alexander Lin; Sirui Ma; Farrokh Dehdashti; Stephanie Markovina; Julie Schwarz; Barry Siegel; Matthew Powell; Perry Grigsby Journal: Int J Gynecol Cancer Date: 2019-02-09 Impact factor: 3.437
Authors: Hongxia Hao; Zhiguo Zhou; Shulong Li; Genevieve Maquilan; Michael R Folkert; Puneeth Iyengar; Kenneth D Westover; Kevin Albuquerque; Fang Liu; Hak Choy; Robert Timmerman; Lin Yang; Jing Wang Journal: Phys Med Biol Date: 2018-05-02 Impact factor: 3.609
Authors: Alexandre Escande; Christine Haie-Meder; Pierre Maroun; Sébastien Gouy; Renaud Mazeron; Thomas Leroy; Enrica Bentivegna; Philippe Morice; Eric Deutsch; Cyrus Chargari Journal: Oncotarget Date: 2016-11-15
Authors: Richard Pötter; Kari Tanderup; Christian Kirisits; Astrid de Leeuw; Kathrin Kirchheiner; Remi Nout; Li Tee Tan; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Peter Hoskin; Kjersti Bruheim; Bhavana Rai; Fleur Huang; Erik Van Limbergen; Max Schmid; Nicole Nesvacil; Alina Sturdza; Lars Fokdal; Nina Boje Kibsgaard Jensen; Dietmar Georg; Marianne Assenholt; Yvette Seppenwoolde; Christel Nomden; Israel Fortin; Supriya Chopra; Uulke van der Heide; Tamara Rumpold; Jacob Christian Lindegaard; Ina Jürgenliemk-Schulz Journal: Clin Transl Radiat Oncol Date: 2018-01-11
Authors: Vanessa A Fabri; Ana C M Queiroz; Henrique Mantoan; Solange M Sanches; Andrea P G Guimarães; Adriana R G Ribeiro; Ronaldo P Souza; Joyce M L Maya; Elizabeth S Santos; Fabrício S Castro; João P N S Lima; Michael J Chen; Glauco Baiocchi; Alexandre A B A da Costa Journal: J Oncol Date: 2019-03-11 Impact factor: 4.375